193 related articles for article (PubMed ID: 34778501)
1. Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab.
Bloomstein JD; Hawkes JE
JAAD Case Rep; 2021 Dec; 18():20-22. PubMed ID: 34778501
[No Abstract] [Full Text] [Related]
2. Recalcitrant prurigo nodularis treated successfully with dupilumab.
Rambhia PH; Levitt JO
JAAD Case Rep; 2019 May; 5(5):471-473. PubMed ID: 31192991
[No Abstract] [Full Text] [Related]
3. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab for prurigo nodularis: Case series and review of the literature.
Holm JG; Agner T; Sand C; Thomsen SF
Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab Treatment for Prurigo Nodularis and Pruritis.
Tanis R; Ferenczi K; Payette M
J Drugs Dermatol; 2019 Sep; 18(9):940-942. PubMed ID: 31524352
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab for the Treatment of Prurigo Nodularis.
Alkhaleefa A; Woo TE; Parsons L
Skin Therapy Lett; 2023 Nov; 28(6):7-9. PubMed ID: 38016088
[TBL] [Abstract][Full Text] [Related]
7. Delayed Hyperpigmented Injection Site Reactions Due to Chronic Dupilumab Use.
Pacheco CS; White KM
Cureus; 2023 Apr; 15(4):e37441. PubMed ID: 37182063
[TBL] [Abstract][Full Text] [Related]
8. Post-Stroke Asymmetric Prurigo Nodularis Responding to Dupilumab Treatment: A Case Report.
Sammarra I; Bennardo L; Provenzano E; Patruno C; Nisticò SP
Brain Sci; 2022 May; 12(5):. PubMed ID: 35624992
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab for Treatment of Prurigo Nodularis: Real-Life Effectiveness for up to 84 Weeks.
Paganini C; Talamonti M; Maffei V; Di Raimondo C; Bianchi L; Galluzzo M
J Clin Med; 2024 Feb; 13(3):. PubMed ID: 38337572
[No Abstract] [Full Text] [Related]
10. Dupilumab as promising treatment for prurigo nodularis: current evidences.
Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
[TBL] [Abstract][Full Text] [Related]
11. Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series.
Wieser JK; Mercurio MG; Somers K
Cureus; 2020 Jun; 12(6):e8737. PubMed ID: 32714676
[TBL] [Abstract][Full Text] [Related]
12. [THREE CASES OF ATOPIC DERMATITIS CHILDREN WITH INTRACTABLE PRURIGO NODULARIS].
Murakami Y; Sugiyama A; Ideguchi H; Murakami Y; Amimoto Y; Nishie H; Odajima H
Arerugi; 2020; 69(3):213-217. PubMed ID: 32435023
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis.
Jonstam K; Swanson BN; Mannent LP; Cardell LO; Tian N; Wang Y; Zhang D; Fan C; Holtappels G; Hamilton JD; Grabher A; Graham NMH; Pirozzi G; Bachert C
Allergy; 2019 Apr; 74(4):743-752. PubMed ID: 30488542
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Dupilumab for the Treatment of Generalized Prurigo Nodularis Phenotype of Adult Atopic Dermatitis.
Napolitano M; Fabbrocini G; Scalvenzi M; Nisticò SP; Dastoli S; Patruno C
Dermatitis; 2020; 31(1):81-84. PubMed ID: 31517666
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Therapy Modulates Circulating Inflammatory Mediators in Patients with Prurigo Nodularis.
Bao A; Ma E; Cornman H; Kambala A; Manjunath J; Kollhoff AL; Imo BU; Kwatra MM; Kwatra SG
JID Innov; 2024 Jul; 4(4):100281. PubMed ID: 38947360
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis.
Maloney NJ; Tegtmeyer K; Zhao J; Worswick S
J Drugs Dermatol; 2019 Oct; 18(10):. PubMed ID: 31603635
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab: Basic aspects and applications to allergic diseases.
Matsunaga K; Katoh N; Fujieda S; Izuhara K; Oishi K
Allergol Int; 2020 Apr; 69(2):187-196. PubMed ID: 32007360
[TBL] [Abstract][Full Text] [Related]
20. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic.
Tanaka M; Aiba S; Matsumura N; Aoyama H; Tagami H
Dermatology; 1995; 190(4):269-76. PubMed ID: 7655104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
